TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05399459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet
Study: NCT04402515
Drug: ICS
Normalized name: ICSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled cortocosteroids
Study: NCT05012761
Drug: SR419 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending single and multiple doses of SR419 orally
Study: NCT05012761
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending single and multiple doses of placebo orally
Study: NCT06800339
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy options include: carboplatin or cisplatin along with pemetrexed, paclitaxel or gemcitabine
Study: NCT06528028
Drug: CAZ/AVI
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous infusion is used
Study: NCT06528028
Drug: CAZ/AVI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2h-infusion is used
Study: NCT05993039
Drug: Remifentanil Injection
Normalized name: remifentanil Injection
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.05-2ug/kg/min adults and children
Study: NCT05755737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo identical in appearance.
Study: NCT05472324
Drug: TQC2731 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQC2731 is a humanized monoclonal antibody based on human thymic stromal lymphopoietin (TSLP) sequence.
Study: NCT05472324
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug is a placebo Comparator.
Study: NCT06271421
Drug: chemotherapy according to Stupp protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide is used during radiotherapy: 75 mg/m2 of body surface area per day for 7 days a week. After the completion of radiotherapy, temozolomide is used as adjuvant therapy - 6 cycles of 150-200 mg/m2 of body surface area for 5 days every 28 days.
Study: NCT05534087
Drug: FOLFOX or CAPOX adjuvant chemotherapy
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. FOLFOX regimen: 6 cycles every 2 weeks~   * Oxaliplatin 85mg/m2 IV infusion over 120 min D1~  * Leucovorin 400mg/m2 IV infusion over 120 min (concurrently with oxaliplatin)~  * 5-fluorouracil 400mg/m2 IV bolus D1~  * 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2 or~2. CAPOX regimen: 4 cycles every 3 weeks~   * Oxaliplatin 130mg/m2 IV infusion over 120 min D1~  * Capecitabine 1,000mg/m2 PO bid D1-14
Study: NCT06508944
Drug: vaginal 17 beta-estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Femiest® Haupt Pharma Munster GMBH, Muenster, Germany~* The assigned dosage will be one vaginal tablet daily for two weeks then one vaginal tablet twice a week for 10 weeks.
Study: NCT06508944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Placebo is produced by Chulalongkorn University Drug and Health Products Innovation \& Promotion Center.~* The assigned dosage will be one vaginal tablet daily for two weeks then one vaginal tablet twice a week for 10 weeks.
Study: NCT06403436
Drug: TT125-802
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT125-802 administered orally
Study: NCT05320367
Drug: Cannabis, placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible participant will be randomize 1:1:1:1:1 to receive placebo, CBD (5mg, 20mg, 50mg and 100mg). Only one research product will be inhaled for each visit. The sequence will depend on the assigned randomization group.
Study: NCT05942027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo match Coenzyme Q10 capsules once per day .
Study: NCT05500599
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Formulation of Fentanyl Citrate and Midazolam Administered Orally for Premedication
Study: NCT06080048
Drug: SOR102
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOR102 capsules
Study: NCT06080048
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules
Study: NCT04910256
Drug: Huatuo Zaizao Pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients take 8g of HuaTuo Zaizao pill three times a day. Treatment lasts for 12 weeks.
Study: NCT06287918
Drug: 3HP-2827
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3HP-2827 will be administered orally once daily in 28-day cycles.
Study: NCT03905109
Drug: ABX464
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 is a new anti-inflammatory drug. In the treatment arm, patients will receive dose A or Dose B of ABX464 orally once daily for 52 weeks.
Study: NCT03905109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the placebo group, patients will receive dose A or B ABX464-matching-placebo orally once daily for 52 weeks.
Study: NCT06085482
Drug: LY3502970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06085482
Drug: [14C]-LY3502970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT05642182
Drug: SFA002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug formula without excipient
Study: NCT05642182
Drug: SFA002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Drug SFA002 with excipient (Propionate)
Study: NCT06178679
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Ophthalmic Solution
Study: NCT04784104
Drug: Adrenaline amp. 0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
Study: NCT00378235
Drug: IL13-PE38QQR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00631501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00631501
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05005520
Drug: DTRI-031
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug
Study: NCT05005520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to DTRI-031
Study: NCT06274528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg; capsule; QD; 6 month duration
Study: NCT05984368
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects injected with Placebo in Part 1 and Part 2
Study: NCT06175702
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 on days 1 to 28 of maintenance
Study: NCT06175702
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 on day 1 of consolidation with 24h infusion; and 20 mg/m2 on days 1, 8, 15 and 22 of maintenance
Study: NCT06175702
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg on days -6 and -5 before alloSCT
Study: NCT04768673
Drug: CKD-393 formulation I
Approvals — FDA: no, EMA: no, PMDA: no
Description: single, oral administration of 2 tablets under fed condition
Study: NCT04768673
Drug: CKD-393 formulation II
Approvals — FDA: no, EMA: no, PMDA: no
Description: single, oral administration of 2 tablets under fed condition
Study: NCT04768673
Drug: D501, D759, H053
Approvals — FDA: no, EMA: no, PMDA: no
Description: single, oral administration of 1 D501, 1 D759 and 2 H053 under fed condition
Study: NCT05801380
Drug: AChE inhibitor monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a drug treatment using Donepezil only
Study: NCT05801380
Drug: AChE inhibitor and NMDA receptor antagonist combination therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a drug treatment combining Donepezil and Memantine
Study: NCT04043598
Drug: Ringer's Lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
Study: NCT00501579
Drug: Prednisolone Acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05800860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via inhalation
Study: NCT04957550
Drug: SHR0302 tablets、Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0302 tablets dose 1 for 48 weeks
Study: NCT04957550
Drug: SHR0302 tablets、Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0302 tablets dose 2 for 48 weeks
Study: NCT04957550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0302 tablets blank preparation for 24 weeks then SHR0302 tablets dose 1/dose 2 for 24 weeks
Study: NCT04557085
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: NCT05973097
Drug: total glucosides of paeony treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total glucosides of paeony capsules were given 0.6 g once, 3 times a day.
Study: NCT06546111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug :placebo tab PO BID for 14 days.
Study: NCT06546111
Drug: Daflon
Normalized name: Daflonex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon 500 mg tab PO BID for 14 days.
Study: NCT05932862
Drug: XL309 (ISM3091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XL309 will be administered orally once daily.
Study: NCT06335173
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Placebo
Study: NCT05363020
Drug: S-Adenosyl-L-Methionine (Sam-E)
Normalized name: S-Adenosyl-L-Methionine (Sam-E)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg capsule
Study: NCT05468138
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Capecitabine 1000mg/m2, orally, twice per day, from day 1 to day 14, Q3W. Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
Study: NCT05363020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg identically appearing placebo
Study: NCT00348244
Drug: Ketorolac, Prednisolone Acetate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05577702
Drug: LBL-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an intravenous infusion
Study: NCT05826353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ophthalmic solution
Study: NCT05399537
Drug: Prismocitrate 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prismocitrate 18 solution (investigational drug) will be used in pre-dilution mode only; the rate of administration depends on the targeted citrate dose and the prescribed flow rate. The pre-filter infusion rate of Prismocitrate 18 solution will be indexed to the blood flow rate (BFR) to achieve a target blood citrate concentration of 3 mmol/L of blood. The flow rate for the anticoagulation of the extracorporeal circuit will be titrated to achieve a post-filter concentration of iCa of 0.25 to 0.35 mmol/L.
Study: NCT06246513
Drug: Glucocorticoid
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet (prophylactic)
Study: NCT04912466
Drug: Biological: IBI322
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant anti-human CD47/PD-L1 bispecific antibody injection
Study: NCT05705414
Drug: Valine
Normalized name: Valine
DrugBank: Valine (DB00161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A medical food intended for use under medical supervision
Study: NCT05705414
Drug: EEA
Normalized name: BREEA SEGETA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: A medical food intended for use under medical supervision
Study: NCT06001112
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 120mg
Study: NCT06144814
Drug: Estrogen vaginal use form
Normalized name: estrogens, conjugated (USP) Vaginal Cream [Premarin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I received 25 µg vaginal estrodiol (Vagifem®). 1 tablet a day for two weeks, then 2 times a week for the next 2 weeks.
Study: NCT04234360
Drug: 5 days of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to this arm will receive an appropriate placebo per os for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
Study: NCT06296212
Drug: TAD® 600 mg/4 mL powder and solvent for solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAD® 600 mg/4 mL powder and solvent for solution for injection, 1 vial powder (glutathione sodium salt 646 mg) + 1 solvent ampoule (4 mL water for injection) reconstituted solution in 50 mL of 0.9% sodium chloride solution) administered intravenously (with an infusion rate of 10 mL/min), 2 times a day (with a dosing interval of 8 hours ± 30 minutes) for 5 consecutive days (Day 1, Day 2, Day 3, Day 4 and Day 5). Doses will be administered at the same time of the day (every 24 hours ± 30 minutes).
Study: NCT05083468
Drug: SR750 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers will be orally administrated by single or multiple dose of SR750 tablet with 240 mL water.
Study: NCT05083468
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers will be orally administrated by single or multiple dose of matching placebo with 240 mL water.
Study: NCT06378125
Drug: Placebo controlled-ileal-release nicotinic acid (SAD/MAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
Study: NCT06378125
Drug: Placebo immediate-release nicotinic acid (SAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
Study: NCT04981860
Drug: Avenova
Normalized name: Avenova
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of 0.01% Avenova will be administered to the inferior conjunctiva of the left eye
Study: NCT06509334
Drug: JYB1904
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JYB1904 at week0 and receive placebo at week4,8,12
Study: NCT06509334
Drug: JYB1904
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JYB1904 at week0,8 and receive placebo at week4,12
Study: NCT04886726
Drug: uhCG/EGF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant
Study: NCT06674109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the placebo arm will take a placebo daily.
Study: NCT05515809
Drug: Standard pain management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pain management care involves a multimodal strategy that includes the use of intravenous analgesics. Morphine medications are the mainstay of pain management
Study: NCT06709638
Drug: Zhilong Huoxue Tongyu capsule
Normalized name: ALCOHOL 42 mL in 60 mL TOPICAL GEL [TongYi CleanGuard Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhilong Huoxue Tongyu capsule
Study: NCT06374771
Drug: Melatonin 10 MG
Normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg of Melatonin will be given orally pre and post-operative
Study: NCT05237297
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 500mg
Study: NCT05237297
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200mg
Study: NCT04542304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given a placebo for the 1-week study period.
Study: NCT04963231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection
Study: NCT05860933
Drug: LY3537982
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05907291
Drug: CRN04894
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
Study: NCT06565208
Drug: SAT-3247
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAT-3247 is an oral tablet that is a potent, muscle penetrant, small molecule inhibitor of AAK1; inhibition of AAK1 rescues perturbed asymmetric division of satellite stem cells, resulting in increased muscle regeneration in animal models of DMD. In vitro and in vivo animal pharmacology studies have demonstrated the efficacy of SAT-3247 in improving muscle strength and the necessary target coverage to maximize functional muscle improvement.
Study: NCT06565208
Drug: matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo
Study: NCT06726174
Drug: ECCEC
Normalized name: Epirubicin Hydrochloride, Cyclophosphamide, Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-1x10\^6 cells/300 uL, intracameral injection.
Study: NCT00508768
Drug: Oral SCIO-469 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03205137
Drug: subjects treated with telmisartan/hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects treated with telmisartan/hydrochlorothiazide
Study: NCT03205137
Drug: subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group
Normalized name: hydrochlorothiazide / telmisartan Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group
Study: NCT05324618
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1% hydrocortisone cream applied on the affected areas twice daily for 4 months.
Study: NCT05323110
Drug: CBS001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.
Study: NCT05323110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBS001 matched placebo
Study: NCT06103188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo pill will be given to the patients 1 hour prior to their planned surgery.
Study: NCT06103188
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin will be given to the patients 1 hour prior to their planned surgery.
Study: NCT04558281
Drug: Placebo erector spinae plane perineural administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administration via an erector spinae plane perineural catheter
Study: NCT05300932
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subject received cyclophosphamide 400mg intravenous drip every 2 weeks combined with oral Prednisone 10-15 mg/d （standard of care）through the 24 weeks double blind period. Subsequently, subject were administered oral Baricitinib 4mg everyday through the 24-48 weeks open label period.
Study: NCT06344442
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine will be administered by continuous infusion. Norepinephrine will be used with final concentrations of 120 microg/ml. The vasopressor infusion will be titrated to maintain an MAP of at least 65 mmHg. The study-drug infusion will be started at 5 ml/h and increased by 2.5 ml/h to achieve a maximum target rate of 30 ml/h, so that NE doses ranged from10 to 60 microg/min.
Study: NCT05085964
Drug: RNA antisense oligonucleotide for intravitreal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: QR-421a will be first administered to the fellow eye (as defined in the preceding study), and will be repeated every 6 months.~Treatment of the study eye (as defined in the preceding study) can commence 3 months (9 months for subjects from study PQ-421a-001) after the treatment of the fellow eye has been initiated and will be repeated every 6 months as well.~Continued subject treatment in this study will be pursued provided that the benefit-risk balance is positive for the individual subject.
Study: NCT04313972
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule nighty for 2 weeks, then 2 capsules nightly for 4 weeks
Study: NCT06039384
Drug: INCB099280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm description
Study: NCT06596005
Drug: TJ0113
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg or 400 mg Capsule, Once Daily
Study: NCT06596005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Once Daily
Study: NCT06598033
Drug: VC plus herbal medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 300 mg/day, TID, PO. Reishi, 2 g/day, BID, PO. Cordyceps, 2 g/day, BID, PO.
Study: NCT06058078
Drug: RY_SW01 cell injection
Normalized name: phenylephrine tannate / pyrilamine tannate Oral Suspension [Ry-T-12]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected RY_SW01 allogonic umbilical cord-derived mesenchymal stem cells(UCMSCs)
Study: NCT06058078
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs for LN treatment
Study: NCT05353985
Drug: TAK-062 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-062 placebo-matching tablets.
Study: NCT06381726
Drug: Up-front Chemotherapy
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide at either 6 cycles consisting of 150-200 mg per square meter for 5 days during each 28-day cycle, or metronomic schedule, + rs-fMRI + neurological and neuropsychological evaluation before starting motor rehabilitation, at 2-3 months during rehabilitation, 6-9 months during rehabilitation, before surgery (if surgery indicated by tumour board), 1 month postop, 2-3 months Post